AAVivo, Inc. announced that Chief Technology Officer and Founder Haifeng Chen, Ph.D., will present the company's breakthrough Precision AAV Capsid Engineering (PACE) platform at BIOHK2025, the Hong Kong International Biotechnology Conference & Exhibition. The presentation, titled "PACE: A Breakthrough AAV Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery," highlights the company's innovative approach to transforming traditional CAR-T therapy development.
Revolutionary PACE Technology Platform
The PACE platform represents a significant advancement in gene delivery technology, enabling the transformation of non-targeted AAV vectors into precise and cell-specific gene delivery vectors. As a core component of AAVivo's IntelligentAAV (iAAV) platform, PACE is designed to allow rapid development of precision biotherapies that can be produced by a patient's body for potent, long-term disease control.
PACE-modified AAV vector therapies can deliver diverse payloads to specific tissues or cell types with three primary therapeutic mechanisms: enhancing immune cell function, redirecting cells in situ to produce targeted therapies locally and persistently, or killing malignant cells directly.
Comprehensive Technology Suite
AAVivo's proprietary platform integrates multiple patented technologies beyond PACE to enable in vivo generation of CAR-T cells, offering a transformative alternative to traditional CAR-T therapies. The company's cutting-edge platform includes BAC-to-AAV Technology for large-scale, cost-effective AAV manufacturing, and the Selective toxin packaging (SToP) platform with microRNA safety shield, ensuring safe delivery of potent therapeutic genes.
These integrated innovations provide higher yields, enhanced potency without the need for lymphodepletion, and superior scalability, unlocking the potential of AAV vectors across diverse indications.
Clinical Pipeline and Market Position
AAVivo's development pipeline includes AVO-100, the company's lead product for B cell malignancies, as well as AVO-200 and AVO-300 for solid tumors. This comprehensive pipeline positions the company as a leader in the rapidly growing gene therapy market, offering a scalable, high-impact biotech platform.
The Houston-based biotechnology company is pioneering novel, precision-targeted biotherapeutics specifically designed to enable in vivo generation of CAR-T cells, representing a significant departure from conventional ex vivo CAR-T manufacturing approaches.
